Cagrilintide 10mg

What is Cagrilintide?

Cagrilintide is a synthetic, long-acting amylin analog peptide developed by Novo Nordisk as a potential treatment for obesity and related metabolic conditions. Amylin itself is a hormone co-secreted with insulin by the pancreas, and it plays a natural role in slowing digestion, controlling appetite, and regulating blood sugar levels.

How Cagrilintide Works (Mechanism of Action)

Cagrilintide’s power lies in its ability to mimic amylin, a hormone that works alongside insulin to regulate food intake and blood sugar. By engineering Cagrilintide as a long-acting amylin analog, researchers have created a peptide that can deliver these effects steadily with once-weekly dosing.

→ Slows gastric emptying: Cagrilintide delays how quickly food leaves the stomach, which helps promote a longer-lasting feeling of fullness after meals.
→ Acts on the brain’s satiety centers: It activates amylin and calcitonin receptors in the hypothalamus, directly influencing the brain regions that control hunger and appetite.
→ Reduces food intake: By increasing satiety signals, it naturally lowers calorie consumption without relying on willpower alone.
→ Improves glucose regulation: Slowing digestion also smooths out post-meal blood sugar spikes, helping stabilize energy and metabolic health.
→ Long half-life advantage: Thanks to its engineered stability, Cagrilintide remains active in the body for days, making it suitable for once-weekly injections — far more convenient than daily appetite-control medications.